Stent restenosis and the use of drug-eluting stents in patients with diabetes mellitus.
Stents have become the technique of choice for percutaneous revascularization, but in-stent restenosis has remained a clinical challenge. This brief article summarizes the incidence, patterns, and proposed mechanisms of restenosis and outlines its contemporary management with specific focus on the diabetic patient. It includes a synopsis of the strategy of drug-eluting stents, which is the most recent and major advance in percutaneous coronary intervention.
Sarembock
Ian J
IJ
Cardiovascular Division and Cardiovascular Research Center, University of Virginia Health System, Box 800158, Charlottesville, VA 22908-0158, USA. ijs4s@virginia.edu
D020099:Coated Materials, Biocompatible; D023903:Coronary Restenosis / Q000209:etiology* / Q000517:prevention & control / Q000628:therapy; D048909:Diabetes Complications; D016503:Drug Delivery Systems; D006801:Humans; D020123:Sirolimus / Q000008:administration & dosage; D015607:Stents / Q000009:adverse effects*
D020099:Coated Materials, Biocompatible; D020123:Sirolimus